Articles · HRT
Monitoring and Adjusting HRT Over Time
What to review, when to change the dose, and how to get HRT working well.
Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.
Starting HRT is the start of a process, not a one-time event. The first prescription is deliberately cautious. Starting doses are low to limit early side effects, the form is picked from a standard set rather than tailored from the start, and the body’s response is not predictable enough to get it right straight away. Most women need at least one dose or form change in the first year, and some need several before they reach a regimen that works well.
Knowing what good ongoing care looks like, what should be reviewed and when, and how to ask for changes, is the difference between HRT that helps a bit and HRT that reliably works.
The Three-Month Review
The three-month review is standard practice after starting HRT and is recommended by NICE guideline NG23.[1] It checks:
- Whether hot flashes and other symptoms have improved, and by how much
- Whether the side effects of the settling-in period have cleared
- Whether the current dose is enough or needs raising
- Whether any unexpected symptoms have appeared
The most common result of a three-month review is a dose increase. Starting doses for transdermal estradiol (usually a 25 to 50 mcg patch, or the gel or spray equivalent) are conservative. Many women need 75 to 100 mcg of transdermal estradiol, or the equivalent, for good symptom control. Poor control at three months is usually a dose issue rather than a sign that HRT is the wrong choice.
If your practice does not offer a three-month review, ask for one. At the appointment, say specifically which symptoms have improved, which have not, and by how much, rather than a general “it’s better” or “it’s not working.” That detail gives your prescriber what they need to make targeted changes.
What “Good Control” Means
There is no universal cut-off for good symptom control, since experience and tolerance vary. A useful benchmark: symptoms should be reduced enough that they are not seriously interfering with sleep, work, mood, or quality of life. The odd mild symptom on some days is not a failure. Daily significant hot flashes despite HRT, or ongoing broken sleep despite adequate estrogen, means the regimen needs review.
Your prescriber should not use “some improvement” as a reason to leave a too-low dose unchanged. The goal is good control, not partial improvement.
Dose Steps for Transdermal Estrogen
Transdermal estradiol doses usually step up like this:
- 25 mcg patch (or gel/spray equivalent): starting dose for most
- 50 mcg: standard effective dose for many women
- 75 mcg: may be needed for good control, especially in early perimenopause when estrogen swings more
- 100 mcg: the top of the standard prescribing range, appropriate for women with significant symptoms not controlled at lower doses
- Above 100 mcg: occasionally used in specialist settings for surgical menopause or specific situations
For gels, the equivalent dose varies by product (Oestrogel, Sandrena, and Lenzetto spray all dose differently). Prescribers should match by estradiol content, not by number of pumps across products.
Give each dose increase at least 6 to 8 weeks before deciding a higher dose is not working, since tissue response takes time to catch up with blood levels.
Adjusting the Progestogen
Women with a womb must take a progestogen with HRT to protect the lining. The most common reason to adjust it is mood. If the progestogen phase (in cyclical regimens) or the continuous low-dose progestogen is causing irritability, low mood, bloating, or PMS-like symptoms, the options are:
Switch from a synthetic progestogen to micronised progesterone. Synthetic progestogens (norethisterone, medroxyprogesterone acetate, levonorgestrel) bind receptors differently and are more likely to cause mood symptoms than micronised progesterone (Utrogestan, Prometrium), which converts to allopregnanolone and has a calming GABA effect. Many women who have significant mood symptoms on a synthetic progestogen tolerate micronised progesterone well.
Switch from cyclical to continuous progestogen. Cyclical regimens produce a withdrawal bleed and a monthly hormone shift that some women find destabilising. Continuous combined HRT (continuous estrogen plus continuous low-dose progestogen) removes that cyclic shift. It suits women who have been postmenopausal for more than a year, or who prefer no bleeding.
Adjust the dose or timing of the progestogen. Some women tolerate it better at a different time of day. Many find micronised progesterone at bedtime works better, since its sedative effect becomes a benefit rather than a burden.
Bleeding on HRT
Cyclical regimens are meant to produce a regular withdrawal bleed. It should be predictable, arriving at about the same time each cycle, and should not be heavy or painful. Irregular bleeding, unpredictable timing, or heavy withdrawal bleeds need a clinical review.
Continuous combined regimens are meant to produce no bleeding once the lining has thinned under continuous progestogen. Irregular spotting and light bleeding is expected in the first 3 to 6 months. Bleeding that lasts beyond 6 months, comes back after a settled stretch of none, or is heavy at any point should be investigated to rule out a problem with the lining. That usually means a transvaginal ultrasound to check lining thickness, and sometimes a biopsy.
Any postmenopausal bleeding (bleeding more than 12 months after the last natural period, in a woman not on HRT or on continuous combined HRT) must be investigated to rule out cancer of the womb lining, whatever the HRT use. No exceptions.
Annual Review
After the settling-in period, NICE recommends an annual HRT review.[1] It should cover:
Symptom control. Are symptoms still well managed? They can change over time: some women need less estrogen as they move further from the transition and symptoms naturally ease; others need a dose increase as their own estrogen production drops further.
Bleeding pattern. Relevant for women moving from cyclical to continuous HRT, or any change in bleeding on a current regimen.
Blood pressure. Transdermal estrogen does not raise blood pressure, but oral estrogen may in some women. A blood pressure check at the annual review is appropriate for everyone on HRT.
Heart risk. Women over 60, or on HRT for more than 10 years, should have their heart risk factors reviewed (cholesterol, blood pressure, glucose, BMI, smoking). This does not mean HRT should be stopped. It means a conversation about the balance of benefit and risk given current health.
Breast health. The annual review is a chance to confirm mammography screening is up to date. In England, routine NHS breast screening runs from age 50 to 70 every 3 years. Women on HRT should make sure they are on the screening register and attending.
Bone health. Women on long-term HRT for symptoms are also getting bone protection as a bonus. Women who stop HRT and have risk factors for osteoporosis may need a DXA scan to decide whether a bone-protective medication is needed.
Libido and sexual function. Often not asked about. If current HRT is not adequately covering sexual function, testosterone may be worth raising at the annual review.
When HRT Is Not Working
If symptoms stay poorly controlled despite dose changes, consider:
Absorption issues. Some women absorb transdermal estradiol less well through the skin, due to skin thickness, application site, or skincare products used on the same area. Switching the site, keeping emollients off that area, or switching form (patch to gel) may help. Blood estradiol can be measured to check whether the dose is actually producing therapeutic levels, though this is a clinical judgement rather than routine.
Thyroid disease. An underactive thyroid produces symptoms that overlap heavily with perimenopause. If HRT is not controlling symptoms, checking thyroid function is worthwhile to rule out an untreated condition alongside.
Low testosterone. Fatigue, low mood, and low libido can persist on estrogen-only regimens if testosterone is also low. Worth raising directly if these symptoms stand out.
Psychological contributors. Poor sleep, anxiety, and depression can keep symptom burden high regardless of estrogen levels. If hot flashes are well controlled but sleep, mood, and brain fog persist, these may need their own assessment and treatment alongside HRT.
Routine Blood Tests
Hormone levels (estradiol, FSH) are not routinely measured during HRT monitoring, except in specific cases: suspected absorption issues, switching between forms, or surgical menopause needing confirmation of physiological replacement. Clinical response (symptom control and side effects) is the main guide to dose adjustment, not the blood level.
References
[1] National Institute for Health and Care Excellence. (2015, updated 2019). Menopause: Diagnosis and management (NICE guideline NG23). NICE. https://www.nice.org.uk/guidance/ng23
Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.